Thijs van der Vaart

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial

Thijs van der Vaart, Ellen Plasschaert, André B. Rietman et al. · The Lancet Neurology · 2013 · 130 citations · Full text

Alzheimer's Disease, Psychiatry, Dementia +10

A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex

Iris E. Overwater, André B. Rietman, Sabine E. Mous et al. · Neurology · 2019 · 125 citations · Full text

HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1

Azar Omrani, Thijs van der Vaart, Edwin Mientjes et al. · Molecular Psychiatry · 2015 · 94 citations · Full text

Cognitive Dysfunction, Neurofibromatosis Type 1, Neuroprotection +8

Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues

Katherine A. Rauen, Susan Huson, Emma Burkitt‐Wright et al. · American Journal of Medical Genetics Part A · 2014 · 56 citations · Full text

Motor deficits in neurofibromatosis type 1 mice: the role of the cerebellum

Thijs van der Vaart, Geeske M. van Woerden, Ype Elgersma et al. · Genes Brain & Behavior · 2011 · 33 citations · Full text